Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Anavex Life Sciences Corp AVXL

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.


NDAQ:AVXL - Post by User

Bullboard Posts
Post by R_J_on Dec 02, 2018 4:06am
72 Views
Post# 29050594

End of Month - November 2018

End of Month - November 2018End of the Month (EOM) report for November 2018.
-
AVXL closed on 11/30/2018 at $2.29
AVXL closed on 10/31/2018 at $2.41
AVXL closed on 09/28/2018 at $2.73
-
This is a   5.0%, a 12-cent, loss for November.
This is a 16.1%, a 44-cent, loss for October & November together.
-
S&P 500 Index, at 2,760.17, gained 1.8% in November. [0.1% below its MA(200) @ 2,761.88]
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's  MA(200) ended November at $2.71
AVXL is now 15.5% below its MA(200).
-
News Release on the AVXL Website in November
-
Nov 8
Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)
-
https://www.anavex.com/anavex-life-sciences-strengthens-its-scientific-advisory-board-with-distinguished-researcher-for-clinical-treatment-of-parkinsons-disease-dementia-pdd/
-
RJ
Bullboard Posts